Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00728) | |||||
---|---|---|---|---|---|
Name |
Vilazodone
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Vilazodone; 163521-12-8; 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide; UNII-S239O2OOV3; EMD 515259; CHEMBL439849; S239O2OOV3; CHEBI:70707; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide; EMD-515259; EMD-68-843; 2-BENZOFURANCARBOXAMIDE, 5-[4-[4-(5-CYANO-1H-INDOL-3-YL)BUTYL]-1-PIPERAZINYL]-; EMD 68843 (Hydrochloride);SB659746A (Hydrochloride); SB 659746A; SB-659746-A; Vilazodone [USAN:INN]; vilazodona; vilazodonum; HSDB 8197; Vilazodone (USAN/INN); 5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide; cc-127; SCHEMBL650682; GTPL7427; yl}-1-benzofuran-2-carboxamide; EX-A174; QCR-275; HMS3744C03; HMS3886N05; BCP05225; ZINC1542113; ANW-63936; BDBM50151982; MFCD09838919; 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine; AKOS015924744; CS-0550; DB06684; PB25213; SB20296; NCGC00371130-03; NCGC00371130-06; AC-25886; AS-73542; HY-14262; AB0044260; EMD 68843;SB 659746A; FT-0675813; D09698; Q-4354; AB01563299_01; L001518; Q408588; 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-; F0001-2418; 1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine; 5-(4-(4-(5-Cyanoindol-3-yl)butyl)-1-piperazinyl)-2-benzofurancarboxamide; 5-{4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl}benzo-furan-2-carboxamide; 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine; 5 -(4-(4-(5 -Cyano-1H-indol-3 -yl)butyl)piperazin-1 -yl)benzofuran-2-carboxamide; 5-{4-[4-(5-Cyano-1H-indol-3-yl)-butyl]-piperazin-1-yl}-benzofuran-2-carboxylic acid amide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Major depressive disorder | ICD-11: 6A70 | [1] | ||
PubChem CID | |||||
Formula |
C26H27N5O2
|
||||
Canonical SMILES |
C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
|
||||
InChI |
1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
|
||||
InChIKey |
SGEGOXDYSFKCPT-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=6918314"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 441.5 | Topological Polar Surface Area | 102 | |
XlogP | 4 | Complexity | 729 | ||
Heavy Atom Count | 33 | Rotatable Bond Count | 7 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Vilazodone 10 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Fd&c red no. 40; Magnesium stearate; Talc; Titanium dioxide; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Allergan; Avera McKennan Hospital | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Allura red AC dye | DIG Info | Solute carrier SLCO2B1 (Ki = 4.7 uM) | [2] | |||
Allura red AC dye | DIG Info | Solute carrier SLCO2B1 (Ki = 2.59 uM) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Vilazodone 20 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Fd&c yellow no. 6; Magnesium stearate; Talc; Titanium dioxide; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Allergan | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Fd&c yellow no. 6; Magnesium stearate; Talc; Titanium dioxide; Silicon dioxide; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Cardinal Health | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Vilazodone 40 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Fd&c blue no. 1; Magnesium stearate; Talc; Titanium dioxide; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Allergan | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 1 | DIG Info | Solute carrier SLCO2B1 (Ki = 13 uM) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Fd&c blue no. 1; Magnesium stearate; Talc; Titanium dioxide; Silicon dioxide; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Cardinal Health | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 1 | DIG Info | Solute carrier SLCO2B1 (Ki = 13 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.